
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
Tenaya Therapeutics Inc., a clinical-stage biotechnology company focused on heart disease therapies, is positioned for a positive outlook due to its promising gene therapy candidates TN-201 and TN-401, with increased projected chances of success from 20% to 30% and from 10% to 15%, respectively. Upcoming readouts in 1H26 and pivotal trial regulatory updates in 2H26 could further validate the efficacy and safety profiles of its therapies, which have already shown significant clinical improvements in patients. The company's innovative approach, evidenced by preclinical data on TN-301, demonstrates potential advantages over existing treatments, enhancing the conviction in its therapeutic portfolio.
Bears say
Tenaya Therapeutics faces significant risks that could adversely affect its stock outlook, primarily linked to potential delays in transitioning preclinical assets to clinical trials and the emergence of safety concerns, such as immune reactions. Additionally, the company may encounter constraints in its manufacturing capacity, which could lead to downward revisions in financial forecasts and negatively impact market sentiment. The variability in patient data, such as the differences in non-sustained ventricular tachycardia (NSVT) burden reductions, raises concerns regarding the consistency and reliability of clinical outcomes that are vital for investor confidence.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares